{"id":"ep4","name":"EP4 (PTGER4)","symbol":"PTGER4","route":"/targets/ep4/","asOf":"2026-11-03","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9596","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171522","uniprot":"https://www.uniprot.org/uniprotkb/P35408/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P35408","open-targets":"https://platform.opentargets.org/target/ENSG00000171522","civic":"https://civicdb.org/genes/5734/summary","oncokb":"https://www.oncokb.org/gene/PTGER4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTGER4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PTGER4","depmap":"https://depmap.org/portal/gene/PTGER4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000171522-PTGER4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5734","omim":"https://www.omim.org/entry/601586"}],"products":[{"id":"inv-1120","name":"INV-1120","status":"phase-1","modality":"EP4 antagonist","route":"/drugs/inv-1120/"}],"trials":[{"id":"nct04443088","name":"An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","nct":"NCT04443088","phase":"1","status":"recruiting"}],"pathways":[],"companies":["shenzhen-ionova-life-sciences"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}